Thank you for visiting our virtual exhibit
PROMETHERA BIOSCIENCES S.A./N.V.
Promethera® Biosciences is a global innovator in liver therapeutics whose mission is to bring patients life-saving treatments to reduce the need for liver transplantation. The Company has developed its cell therapy technologies by using allogeneic stem and progenitor liver cells. Promethera®’s lead clinical program, derived from its patented cell technology platform HepaStem™, is designed to benefit from its immune-modulatory and anti-fibrotic properties. The Company has strengthened its development portfolio by developing antibody technologies, such as the anti-TNF-R1 antibody Atrosimab to complement its therapeutics options. Promethera®’s team is composed of international experts operating in Belgium, USA, Japan & Switzerland.
•A worldwide company with a local presence in 4 countries.
•A unique set of technological assets to bring life-saving treatments to reduce the need for liver transplantation.
•Largest liver sourcing and unique supply chain on a global basis.
•Robust investor consortium.
RANGE OF PRODUCTS
•HepaStem™ for ACLF (IM) in Phase 2B
•HepaStem™ for NASH/Fibrosis starting Phase 2A
•H2Stem® for Tissue Repair in Pre-Clinical phase
•Atrosimab for NASH/Fibrosis in Pre-Clinical Phase
Luc OTTEN, Chief Scientific Officer
Mobile : +32 478 78 10 47
E-mail : email@example.com
Victoria BETOESKI, Global Associate Director Strategic Planning & Corporate Development
Mobile : +32 470 98 08 99
E-mail : firstname.lastname@example.org